A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS)
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Frexalimab (Primary) ; Frexalimab (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms phaethuSA
- Sponsors Sanofi
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.
- 24 Nov 2023 The trial has been completed in Belgium, according to European Clinical Trials Database record.
- 25 Aug 2023 Planned End Date changed from 15 Jan 2024 to 1 Feb 2024.